Antimicrobial resistance in European isolates of Pseudomonas aeruginosa

A. C. Fluit, J. Verhoef, F. J. Schmitz, H. Mittermayer, M. Struelens, F. Goldstein, V. Jarlier, J. Etienne, P. R. Courcol, F. Daschner, U. Hadding, N. Legakis, G. C. Schito, G. Raponi, P. Heczko, W. Hyrniewicz, D. Costa, E. Perea, F. Baquero, R. Martin AlvarezJ. Bille, G. French, R. Andoni, V. Korten, S. Unal, D. Gür, N. Keller

Research output: Contribution to journalArticlepeer-review

47 Scopus citations


Pseudomonas aeruginosa is responsible for a substantial fraction of hospital infections. Twenty-five European university hospitals submitted a total of 1411 Pseudomonas aeruginosa isolates for susceptibility testing during 1997 and 1998. The isolates showed highest susceptibility to amikacin (87.5%), meropenem (87.3%) and piperacillin/tazobactam (86.8%). Susceptibility to ciprofloxacin was 73.2%. There was no clear geographical distribution of resistance, although isolates from northwestern Europe tended to be more susceptible than those from southeastern Europe. Isolates that were resistant to one class of antibiotics were also often resistant to at least one other class of antibiotics. Imipenem-resistant isolates were generally not clonally related.

Original languageEnglish
Pages (from-to)370-374
Number of pages5
JournalEuropean Journal of Clinical Microbiology and Infectious Diseases
Issue number5
StatePublished - 2000


Dive into the research topics of 'Antimicrobial resistance in European isolates of Pseudomonas aeruginosa'. Together they form a unique fingerprint.

Cite this